Company Expects Q4 2025 Revenue of Approximately $772 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
The company states: "Reported and organic revenue growth for the fourth quarter is expected to be approximately 6% and 4%, respectively, as compared to the same period a year ago. This is expected to result in fourth quarter revenue of approximately $772 million. For the full year 2025, reported and organic revenue growth is expected to be approximately 4% and 3%, respectively, as compared to the same period a year ago. This is expected to result in full year 2025 revenue of approximately $2,855 million. As previously announced, Prahlad Singh, will present at 9:45 a.m. PT tomorrow (January 13, 2026) at the 44th annual J.P. Morgan Healthcare Conference."
Get Free Real-Time Notifications for Any Stock
Monitor tickers like RVTY with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on RVTY
Wall Street analysts forecast RVTY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVTY is 113.38 USD with a low forecast of 105.00 USD and a high forecast of 123.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
6 Buy
4 Hold
0 Sell
Moderate Buy
Current: 111.130
Low
105.00
Averages
113.38
High
123.00
Current: 111.130
Low
105.00
Averages
113.38
High
123.00
About RVTY
Revvity, Inc. is a provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. The Company has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The segment offers instruments, reagents, software, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
10 Healthcare Stocks with A+ EPS Revision Ratings Attracting Investor Attention
- EPS Rating Upgrade: Ten healthcare stocks have received the highest A+ EPS revision rating from analysts, indicating increased confidence in their profitability outlook, which may attract more investor interest.
- List of Companies: Companies such as Cardinal Health (CAH) and HCA Healthcare (HCA) have achieved A+ ratings, showcasing strong earnings expectations that could drive their stock prices higher.
- Market Reaction: As analysts revise their earnings estimates upward for these companies, investors may reassess their portfolios, thereby increasing overall market attention on healthcare stocks.
- Industry Trends: With the earnings season underway, the robust performance of healthcare stocks and positive analyst revisions may signal a sector recovery, further attracting capital inflows into this area.
Continue Reading
Revvity, Inc. (RVTY) Projects 6% Q4 Revenue Growth Amid Market Pressure
- Earnings Expectations: Revvity anticipates a 6% revenue growth for Q4 2025, reaching approximately $772 million, surpassing the consensus of $760.6 million, indicating the company's resilience in a competitive market.
- Profitability Outlook: The company expects adjusted earnings per share for 2025 to exceed the upper end of its previous guidance of $4.90 to $5.00, reflecting management's confidence in future profitability, which may attract more investor interest.
- Market Performance: Despite broader market pressures, Revvity's stock rose 6.02% on Tuesday, closing at $110.14, demonstrating positive investor sentiment towards its financial outlook and recognition of its growth potential.
- Analyst Ratings: The stock carries a “Buy” rating with an average price target of $120.24, as analysts generally favor its future performance, especially with an expected 8% earnings growth, further solidifying its market position.
Continue Reading